Several other research analysts have also recently weighed in on the stock. Zacks Investment Research upgraded shares of ObsEva SA from a sell rating to a buy rating and set a $11.00 price target for the company in a report on Wednesday, October 18th. Credit Suisse Group assumed coverage on shares of ObsEva SA in a report on Monday, October 9th. They issued an outperform rating and a $16.00 price target for the company. Royal Bank Of Canada assumed coverage on shares of ObsEva SA in a report on Thursday, September 14th. They issued an outperform rating and a $22.00 price target for the company. Finally, Leerink Swann reiterated an outperform rating and issued a $18.00 price target on shares of ObsEva SA in a report on Wednesday, August 16th. Six equities research analysts have rated the stock with a buy rating, ObsEva SA has an average rating of Buy and a consensus price target of $18.83.
ObsEva SA (NASDAQ:OBSV) last released its quarterly earnings results on Tuesday, August 15th. The company reported ($0.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.13). During the same quarter in the prior year, the business posted ($0.30) EPS.
COPYRIGHT VIOLATION NOTICE: “HC Wainwright Analysts Give ObsEva SA (OBSV) a $25.00 Price Target” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/11/02/hc-wainwright-analysts-give-obseva-sa-obsv-a-25-00-price-target.html.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sectoral Asset Management Inc boosted its holdings in ObsEva SA by 181.9% during the second quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock worth $1,820,000 after purchasing an additional 137,331 shares during the last quarter. VHCP Management II LLC acquired a new position in ObsEva SA during the second quarter worth $1,283,000. Sphera Funds Management LTD. boosted its holdings in ObsEva SA by 9.7% during the second quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock worth $1,979,000 after purchasing an additional 20,411 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new position in ObsEva SA during the first quarter worth $131,000. Institutional investors and hedge funds own 48.46% of the company’s stock.
ObsEva SA Company Profile
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
What are top analysts saying about ObsEva SA? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ObsEva SA and related companies.